Population pharmacokinetics of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation

Written By CCRG

Abdul-Aziz, M., Cheng, V., Burrows, F., Buscher, H., Cho, Y., Corley, A., Diehl, A., Gilder, E., Kim, H., Levkovich, B., Lim, S., Liu, X., McGuinness, S., Ordonez, J., Parke, R., Pellegrino, V., Reynolds, C., Rudham, S., Wallis, S., Welch, S., Fraser, J., Shekar, K., Roberts, J. Journal of Antimicrobial Chemotherapy DOI: 10.1093/jac/dkag090

Abstract: To describe meropenem population pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation (ECMO) with or without renal replacement therapy (RRT), and to identify dosing regimens likely to achieve safe and effective exposures.

Read more
CCRG
Previous

Animal models of critical illness in the Asia–Pacific region
Next

Evidence-based guidelines for the use of extracorporeal membrane oxygenation in Australia and New Zealand using GRADE methodology series part 1